Suven Life Sciences Limited (BOM:530239)

Market Cap	64.88B
Revenue (ttm)	66.56M
Net Income (ttm)	-1.61B
Shares Out	218.07M
EPS (ttm)	-7.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,044
Average Volume	27,149
Open	277.50
Previous Close	275.60
Day's Range	277.50 - 289.35
52-Week Range	102.70 - 289.35
Beta	0.78
RSI	71.58
Earnings Date	Aug 13, 2025

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 141
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In 2024, Suven Life Sciences's revenue was 66.56 million, a decrease of -43.08% compared to the previous year's 116.93 million. Losses were -1.61 billion, 53.0% more than in 2023.